BRCA2 and non-small cell lung carcinoma: Though no validated biomarker has been identified for antiangiogenic drugs, study on NSCLC indicated that genetic alternations of ARID1A, BRCA2 and IDHexon4 could potentially be used to guide anlotinib therapy.27